A systematic review of hepatitis B screening economic evaluations in low- and middle-income countries.

ABSTRACT:

Background

Chronic hepatitis B infection is a significant cause of morbidity and mortality worldwide; low- and middle-income countries (LMICs) are disproportionately affected. Economic evaluations are a useful decision tool to assess costs versus benefits of hepatitis B virus (HBV) screening. No published study reviewing economic evaluations of HBV screening in LMICs has been undertaken to date.

Methods

The following databases were searched from inception to 21 April 2017: MEDLINE, PubMed, EMBASE, CINAHL Plus, the Cochrane Library, Global Health and the Cost-effectiveness Analysis Registry. English-language studies were included if they assessed the costs against the benefits of HBV screening in LMICs. PROSPERO registration: CRD42015024391, 20 July 2015.

Results

Nine

SUBMITTER: Wright CM 

PROVIDER: S-EPMC5859762 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature